<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35401521</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Age-Associated Seroprevalence of Coronavirus Antibodies: Population-Based Serosurveys in 2013 and 2020, British Columbia, Canada.</ArticleTitle><Pagination><StartPage>836449</StartPage><MedlinePgn>836449</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">836449</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.836449</ELocationID><Abstract><AbstractText Label="BACKGROUND">Older adults have been disproportionately affected during the SARS-CoV-2 pandemic, including higher risk of severe disease and long-COVID. Prior exposure to endemic human coronaviruses (HCoV) may modulate the response to SARS-CoV-2 infection and contribute to age-related observations. We hypothesized that cross-reactive antibodies to SARS-CoV-2 are associated with antibodies to HCoV and that both increase with age.</AbstractText><AbstractText Label="METHODS">To assess SARS-CoV-2 unexposed individuals, we drew upon archived anonymized residual sero-surveys conducted in British Columbia (BC), Canada, including before SARS-CoV-2 emergence (May, 2013) and before widespread community circulation in BC (May, 2020). Fifty sera, sex-balanced per ten-year age band, were sought among individuals &#x2264;10 to &#x2265;80 years old, supplemented as indicated by sera from March and September 2020. Sera were tested on the Meso Scale Diagnostics (MSD) electrochemiluminescent multiplex immunoassay to quantify IgG antibody against the Spike proteins of HCoV, including alpha (HCoV-229E, HCoV-NL63) and beta (HCoV-HKU1, HCoV-OC43) viruses, and the 2003 epidemic beta coronavirus, SARS-CoV-1. Cross-reactive antibodies to Spike, Nucleocapsid, and the Receptor Binding Domain (RBD) of SARS-CoV-2 were similarly measured, with SARS-CoV-2 sero-positivity overall defined by positivity on &#x2265;2 targets.</AbstractText><AbstractText Label="RESULTS">Samples included 407 sera from 2013, of which 17 were children &#x2264;10 years. The 2020 samples included 488 sera, of which 88 were children &#x2264;10 years. Anti-Spike antibodies to all four endemic HCoV were acquired by 10 years of age. There were 20/407 (5%) sera in 2013 and 8/488 (2%) in 2020 that were considered sero-positive for SARS-CoV-2 based on MSD testing. Of note, antibody to the single SARS-CoV-2 RBD target was detected in 329/407 (81%) of 2013 sera and 91/488 (19%) of 2020 sera. Among the SARS-CoV-2 overall sero-negative population, age was correlated with anti-HCoV antibody levels and these, notably 229E and HKU1, were correlated with cross-reactive anti-SARS-CoV-2 RBD titres. SARS-CoV-2 overall sero-positive individuals showed higher titres to HCoV more generally.</AbstractText><AbstractText Label="CONCLUSION">Most people have an HCoV priming exposure by 10 years of age and IgG levels are stable thereafter. Anti-HCoV antibodies can cross-react with SARS-CoV-2 epitopes. These immunological interactions warrant further investigation with respect to their implications for COVID-19 clinical outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Tanunliong, Liu, Kaweski, Irvine, Reyes, Purych, Krajden, Morshed, Sekirov, Gantt, Skowronski and Jassem.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tanunliong</LastName><ForeName>Guadalein</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Aaron C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaweski</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irvine</LastName><ForeName>Mike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>British Columbia Centre for Disease Control, Vancouver, BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyes</LastName><ForeName>Romina C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LifeLabs, Burnaby, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purych</LastName><ForeName>Dale</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surrey Memorial Hospital, Fraser Health Authority, Surrey, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krajden</LastName><ForeName>Mel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morshed</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sekirov</LastName><ForeName>Inna</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gantt</LastName><ForeName>Soren</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Pediatrics and Microbiology, Infectious Diseases &amp; Immunology, University of Montreal, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sainte-Justine University Hospital Centre, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skowronski</LastName><ForeName>Danuta M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Communicable Diseases and Immunization Services, British Columbia Centre for Disease Control, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jassem</LastName><ForeName>Agatha N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001955" MajorTopicYN="N" Type="Geographic">British Columbia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 severity</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibodies</Keyword><Keyword MajorTopicYN="N">cross-reactive antibodies</Keyword><Keyword MajorTopicYN="N">endemic coronavirus</Keyword><Keyword MajorTopicYN="N">humoral immune response</Keyword></KeywordList><CoiStatement>Author RR was employed by company LifeLabs. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>11</Day><Hour>5</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35401521</ArticleId><ArticleId IdType="pmc">PMC8984254</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.836449</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . WHO Coronavirus (COVID-19) Dashboard. (2021).</Citation></Reference><Reference><Citation>Lu L, Zhong W, Bian Z, Li Z, Zhang K, Liang B, et al. . A Comparison of Mortality-Related Risk Factors of COVID-19, SARS, and MERS: A Systematic Review and Meta-Analysis. J Infect WB Saunders Ltd (2020) 81:e18&#x2013;25. doi: 10.1016/j.jinf.2020.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.07.002</ArticleId><ArticleId IdType="pmc">PMC7334925</ArticleId><ArticleId IdType="pubmed">32634459</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P, Curtis N. Why Is COVID-19 Less Severe in Children? A Review of the Proposed Mechanisms Underlying the Age-Related Difference in Severity of SARS-CoV-2 Infections. Vol. 0, Archives of Disease in Childhood. BMJ Publishing Group (2020) 106:429&#x2013;39. doi: 10.1136/archdischild-2020-320338</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2020-320338</ArticleId><ArticleId IdType="pubmed">33262177</ArticleId></ArticleIdList></Reference><Reference><Citation>Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. . The SARS, MERS and Novel Coronavirus (COVID-19) Epidemics, the Newest and Biggest Global Health Threats: What Lessons Have We Learned? Int J Epidemiol (2020) 49(3):717&#x2013;26. doi: 10.1093/ije/dyaa033</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyaa033</ArticleId><ArticleId IdType="pmc">PMC7197734</ArticleId><ArticleId IdType="pubmed">32086938</ArticleId></ArticleIdList></Reference><Reference><Citation>Fosb&#xf8;l EL, Butt JH, &#xd8;stergaard L, Andersson C, Selmer C, Kragholm K, et al. . Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. JAMA - J Am Med Assoc (2020) 324(2):168&#x2013;77. doi: 10.1001/jama.2020.11301</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.11301</ArticleId><ArticleId IdType="pmc">PMC7305566</ArticleId><ArticleId IdType="pubmed">32558877</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. . A Systematic Review of Antibody Mediated Immunity to Coronaviruses: Kinetics, Correlates of Protection, and Association With Severity. Nat Commun (2020) 11(1):4704. doi: 10.1038/s41467-020-18450-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18450-4</ArticleId><ArticleId IdType="pmc">PMC7499300</ArticleId><ArticleId IdType="pubmed">32943637</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelghany TM, Ganash M, Bakri MM, Qanash H, Al-Rajhi AMH, Elhussieny NI. SARS-CoV-2, The Other Face to SARS-CoV and MERS-CoV: Future Predictions. BioMed J (2021) 44(1):86&#x2013;93. doi: 10.1016/j.bj.2020.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bj.2020.10.008</ArticleId><ArticleId IdType="pmc">PMC7603957</ArticleId><ArticleId IdType="pubmed">33602634</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu DX, Liang JQ, Fung TS. Human Coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae). Bamford DH, Zuckerman M, Editors. Encycl Virol (2021) 2:428&#x2013;40. doi: 10.1016/B978-0-12-809633-8.21501-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-809633-8.21501-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamminen K, Salminen M, Blazevic V. Seroprevalence and SARS-CoV-2 Cross-Reactivity of Endemic Coronavirus OC43 and 229E Antibodies in Finnish Children and Adults. Clin Immunol (2021) 229:108782. doi: 10.1016/j.clim.2021.108782</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108782</ArticleId><ArticleId IdType="pmc">PMC8188772</ArticleId><ArticleId IdType="pubmed">34118402</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung TS, Liu DX. Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases. Annu Rev Microbiol (2021) 75(1):1&#x2013;29. doi: 10.1146/annurev-micro-110520-023212</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-micro-110520-023212</ArticleId><ArticleId IdType="pubmed">33492978</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, Wang W, Wang H, Lu R, Tan W. First Infection by All Four non-Severe Acute Respiratory Syndrome Human Coronaviruses Takes Place During Childhood. BMC Infect Dis (2013) 13(1):433. doi: 10.1186/1471-2334-13-433</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-13-433</ArticleId><ArticleId IdType="pmc">PMC3848659</ArticleId><ArticleId IdType="pubmed">24040960</ArticleId></ArticleIdList></Reference><Reference><Citation>Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, Loens K, et al. . Seasonal Coronavirus Protective Immunity is Short-Lasting. Nat Med (2020) 26(11):1691&#x2013;3. doi:&#xa0;10.1038/s41591-020-1083-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1083-1</ArticleId><ArticleId IdType="pubmed">32929268</ArticleId></ArticleIdList></Reference><Reference><Citation>Callow KA, Parry HF, Sergeant M, Tyrrell DA. The Time Course of the Immune Response to Experimental Coronavirus Infection of Man. Epidemiol Infect (1990) 105(2):435&#x2013;46. doi: 10.1017/S0950268800048019</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268800048019</ArticleId><ArticleId IdType="pmc">PMC2271881</ArticleId><ArticleId IdType="pubmed">2170159</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. . Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans With COVID-19 Disease and Unexposed Individuals. Cell (2020) 181(7):1489&#x2013;501. doi: 10.1016/j.cell.2020.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen-Contant P, Embong AK, Kanagaiah P, Chaves FA, Yang H, Branche AR, et al. . S Protein-Reactive IgG and Memory B Cell Production After Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit. MBio (2020) 11(5):e01991&#x2013;20. doi: 10.1128/mBio.01991-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01991-20</ArticleId><ArticleId IdType="pmc">PMC7520599</ArticleId><ArticleId IdType="pubmed">32978311</ArticleId></ArticleIdList></Reference><Reference><Citation>Song G, He WT, Callaghan S, Anzanello F, Huang D, Ricketts J, et al. . Cross-Reactive Serum and Memory B Cell Responses to Spike Protein in SARS-CoV-2 and Endemic Coronavirus Infection. bioRxiv (2020). doi: 10.1101/2020.09.22.308965</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.22.308965</ArticleId><ArticleId IdType="pmc">PMC8134462</ArticleId><ArticleId IdType="pubmed">34011939</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, et al. . Viral Epitope Profiling of COVID-19 Patients Reveals Cross-Reactivity and Correlates of Severity. Science (80-) (2020) 370(6520):eabd4250. doi:&#xa0;10.1126/science.abd4250</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4250</ArticleId><ArticleId IdType="pmc">PMC7857405</ArticleId><ArticleId IdType="pubmed">32994364</ArticleId></ArticleIdList></Reference><Reference><Citation>Majdoubi A, Michalski C, O&#x2019;Connell SE, Dada S, Narpala SR, Gelinas JP, et al. . A Majority of Uninfected Adults Show Pre-Existing Antibody Reactivity Against SARS-CoV-2. JCI Insight (2021) 6(8):e146316. doi: 10.1172/jci.insight.146316</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.146316</ArticleId><ArticleId IdType="pmc">PMC8119195</ArticleId><ArticleId IdType="pubmed">33720905</ArticleId></ArticleIdList></Reference><Reference><Citation>Tso FY, Lidenge SJ, Pe&#xf1;a PB, Clegg AA, Ngowi JR, Mwaiselage J, et al. . High Prevalence of Pre-Existing Serological Cross-Reactivity Against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in Sub-Saharan Africa. Int J Infect Dis (2021) 102:577&#x2013;83. doi: 10.1016/j.ijid.2020.10.104</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.10.104</ArticleId><ArticleId IdType="pmc">PMC7648883</ArticleId><ArticleId IdType="pubmed">33176202</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrwani K, Sharma R, Krishnan M, Jones T, Mayora-Neto M, Cantoni D, et al. . Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post&#x2013;COVID-19 Convalescent Samples. J Infect Dis (2021) 224(8):1305&#x2013;15. doi: 10.1093/infdis/jiab333</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab333</ArticleId><ArticleId IdType="pmc">PMC8557674</ArticleId><ArticleId IdType="pubmed">34161567</ArticleId></ArticleIdList></Reference><Reference><Citation>Skowronski DM, Sekirov I, Sabaiduc S, Zou M, Morshed M, Lawrence D, et al. . Low SARS-CoV-2 Sero-Prevalence Based on Anonymized Residual Sero-Survey Before and After First Wave Measures in British Columbia, Canada, March-May 2020. medRxiv (2020). doi: 10.1101/2020.07.13.20153148</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.13.20153148</ArticleId></ArticleIdList></Reference><Reference><Citation>Li FF, Liu A, Gibbs E, Tanunliong G, Marquez AC, Gantt S, et al. . A Novel Multiplex Electrochemiluminescent Immunoassay for Detection and Quantification of Anti-SARS-CoV-2 IgG and Anti-Seasonal Endemic Human Coronavirus IgG. J Clin Virol (2022) 146:105050. doi: 10.1016/j.jcv.2021.105050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2021.105050</ArticleId><ArticleId IdType="pmc">PMC8632860</ArticleId><ArticleId IdType="pubmed">34883405</ArticleId></ArticleIdList></Reference><Reference><Citation>Killerby ME, Biggs HM, Haynes A, Dahl RM, Mustaquim D, Gerber SI, et al. . Human Coronavirus Circulation in the United States 2014-2017. J Clin Virol (2018) 101:52&#x2013;6. doi: 10.1016/j.jcv.2018.01.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2018.01.019</ArticleId><ArticleId IdType="pmc">PMC7106380</ArticleId><ArticleId IdType="pubmed">29427907</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicks J, Klumpp-Thomas C, Kalish H, Shunmugavel A, Mehalko J, Denson JP, et al. . Serologic Cross-Reactivity of SARS-CoV-2 With Endemic and Seasonal Betacoronaviruses. medRxiv (2020). doi: 10.1101/2020.06.22.20137695</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.22.20137695</ArticleId><ArticleId IdType="pmc">PMC7962425</ArticleId><ArticleId IdType="pubmed">33725211</ArticleId></ArticleIdList></Reference><Reference><Citation>Merkuleva IA, Shcherbakov DN, Borgoyakova MB, Shanshin DV, Rudometov AP, Karpenko LI, et al. . Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems. Vaccines (2022) 10(1):96. doi: 10.3390/vaccines10010096</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10010096</ArticleId><ArticleId IdType="pmc">PMC8779843</ArticleId><ArticleId IdType="pubmed">35062757</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang B, Cai Y, Li N, Li K, Wang Z, Li L, et al. . Sex-Based Clinical and Immunological Differences in COVID-19. BMC Infect Dis (2021) 21(1):647. doi:&#xa0;10.1186/s12879-021-06313-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06313-2</ArticleId><ArticleId IdType="pmc">PMC8256650</ArticleId><ArticleId IdType="pubmed">34225644</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagar M, Reifler K, Rossi M, Miller NS, Sinha P, White LF, et al. . Recent Endemic Coronavirus Infection Is Associated With Less-Severe COVID-19. J Clin Invest (2021) 131(1):e143380. doi: 10.1172/JCI143380</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI143380</ArticleId><ArticleId IdType="pmc">PMC7773342</ArticleId><ArticleId IdType="pubmed">32997649</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugas M, Grote-Westrick T, Vollenberg R, Lorentzen E, Brix T, Schmidt H, et al. . Less Severe Course of COVID-19 is Associated With Elevated Levels of Antibodies Against Seasonal Human Coronaviruses OC43 and HKU1 (HCoV OC43, HCoV Hku1). Int J Infect Dis IJID Off Publ Int Soc Infect Dis (2021) 105:304&#x2013;6. doi: 10.1016/j.ijid.2021.02.085</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.02.085</ArticleId><ArticleId IdType="pmc">PMC7901274</ArticleId><ArticleId IdType="pubmed">33636357</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerhuis BM, Aguilar-Bretones M, Raadsen MP, de Bruin E, Okba NMA, Haagmans BL, et al. . Severe COVID-19 Patients Display a Back Boost of Seasonal Coronavirus-Specific Antibodies. medRxiv (2020). doi: 10.1101/2020.10.10.20210070</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.10.20210070</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilar-Bretones M, Westerhuis BM, Raadsen MP, de Bruin E, Chandler FD, Okba NMA, et al. . Seasonal Coronavirus&#x2013;Specific B Cells With Limited SARS-CoV-2 Cross-Reactivity Dominate the IgG Response in Severe COVID-19. J Clin Invest (2021) 131(21):e150613. doi: 10.1172/JCI150613</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI150613</ArticleId><ArticleId IdType="pmc">PMC8553556</ArticleId><ArticleId IdType="pubmed">34499051</ArticleId></ArticleIdList></Reference><Reference><Citation>Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. . Clinical and Immunological Assessment of Asymptomatic SARS-CoV-2 Infections. Nat Med (2020) 26(8):1200&#x2013;4. doi: 10.1038/s41591-020-0965-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0965-6</ArticleId><ArticleId IdType="pubmed">32555424</ArticleId></ArticleIdList></Reference><Reference><Citation>Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, et al. . The Receptor-Binding Domain of the Viral Spike Protein is an Immunodominant and Highly Specific Target of Antibodies in SARS-CoV-2 Patients. Sci Immunol (2020) 5(48):eabc8413. doi:&#xa0;10.1126/sciimmunol.abc8413</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abc8413</ArticleId><ArticleId IdType="pmc">PMC7292505</ArticleId><ArticleId IdType="pubmed">32527802</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>